Novartis AG Registered Shares NVSEF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVSEF is a good fit for your portfolio.
News
-
Novartis Gets Priority Review for Kidney Disease Treatment
-
Trending: Novartis Begins Tender Offer for MorphoSys Shares
-
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
-
Novartis Adjusts Manufacturing of Breast Cancer Drug Ribociclib
-
Novartis Says Early Addition of Cholesterol Drug Shows Positive Results in Trial
-
Novartis Shares Rise After Trial Data Supports New Filing for Cancer Drug
-
Novartis, Roche's Food Allergies Treatment Xolair Gets FDA Approval
-
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk
Trading Information
- Previous Close Price
- $94.10
- Day Range
- $93.64–94.25
- 52-Week Range
- $90.92–108.50
- Bid/Ask
- $90.82 / $95.69
- Market Cap
- $191.40 Bil
- Volume/Avg
- 2,874 / 101,842
Key Statistics
- Price/Earnings (Normalized)
- 14.05
- Price/Sales
- 4.29
- Dividend Yield (Trailing)
- 4.00%
- Dividend Yield (Forward)
- 4.55%
- Total Yield
- 8.47%
Company Profile
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 76,057
- Website
- https://www.novartis.com
Competitors
Valuation
|
Metric
|
NVSEF
|
GSK
|
JNJ
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.05 | 10.60 | 14.40 |
Price/Book Value | 4.19 | 4.77 | 5.26 |
Price/Sales | 4.29 | 2.23 | 4.52 |
Price/Cash Flow | 13.72 | 10.62 | 18.96 |
Price/Earnings
NVSEF
GSK
JNJ
Financial Strength
|
Metric
|
NVSEF
|
GSK
|
JNJ
|
|---|---|---|---|
Quick Ratio | 0.88 | 0.59 | 0.91 |
Current Ratio | 1.16 | 0.88 | 1.16 |
Interest Coverage | 10.94 | 9.30 | 18.88 |
Quick Ratio
NVSEF
GSK
JNJ
Profitability
|
Metric
|
NVSEF
|
GSK
|
JNJ
|
|---|---|---|---|
Return on Assets (Normalized) | 12.15% | 10.54% | 13.98% |
Return on Equity (Normalized) | 27.10% | 50.48% | 35.02% |
Return on Invested Capital (Normalized) | 17.72% | 21.33% | 22.24% |
Return on Assets
NVSEF
GSK
JNJ
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Scsdlhyzh | Cpg | $713.8 Bil | |
JNJ
| Johnson & Johnson | Cvxdqkztr | Hbvs | $361.9 Bil | |
MRK
| Merck & Co Inc | Kvzxfzms | Nlkg | $319.6 Bil | |
ABBV
| AbbVie Inc | Bkwpnrydb | Vhlm | $286.3 Bil | |
AZN
| AstraZeneca PLC ADR | Sgcpggnrn | Qcm | $213.0 Bil | |
RHHBY
| Roche Holding AG ADR | Pqynpbnrw | Fpsz | $198.4 Bil | |
NVS
| Novartis AG ADR | Ztvlfcg | Yjy | $193.5 Bil | |
PFE
| Pfizer Inc | Bkrrwxbzj | Pqfl | $146.7 Bil | |
AMGN
| Amgen Inc | Pmgfwvgq | Gkhfd | $142.3 Bil | |
SNY
| Sanofi SA ADR | Hqcvdmsg | Bpzm | $116.2 Bil |